Comparative therapeutic activity of the nitrogen mustards and allied compounds (Q73975871)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13308491%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

title

Comparative therapeutic activity of the nitrogen mustards and allied compounds (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13308491%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

author name string

M P SYKES

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13308491%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

F S PHILLIPS

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13308491%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

D A KARNOFSKY

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13308491%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

publication date

1 May 1956

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13308491%20AND%20SRC:MED&resulttype=core&format=json

Medical Clinics of North America

8 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13308491%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

volume

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13308491%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13308491%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

page(s)

837-856

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13308491%20AND%20SRC:MED&resulttype=core&format=json

Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders

8 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Nitrogen mustards in the treatment of neoplastic disease; official statement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

The Biological Actions and Therapeutic Applications of the B-Chloroethyl Amines and Sulfides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Chemotherapy of neoplastic disease; agents of clinical value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Chemotherapy of malignant disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

The newer nitrogen mustards in the treatment of leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Effects upon tumours of Various Haloalkylarylamines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

A trial of beta-naphthyldi-2-chloroethylamine in leukemia, Hodgkin's disease, and allied diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Clinical trials of p-(di-2-chloroethylamino)-phenylbutyric acid (CB 1348) in malignant lymphoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Myleran in chronic myeloid leukaemia; results of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Effect of 2-chloro-2'-hydroxydiethyl sulfide (hemisulfur mustard) on carcinomatosis with ascites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

EXPERIMENTAL AND CLINICAL STUDIES ON THE TREATMENT OF CANCER BY DICHLORETHYLSULPHIDE (MUSTARD GAS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

A comparison of the effects of radiation and radiomimetic chemicals on the blood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Treatment of Hodgkin's disease and the lymphosarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Nitrogen mustard as a therapeutic agent for Hodgkin's disease, lymphosarcoma and leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

The clinical effect of nitrogen mustard on Hodgkin's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

The role of nitrogen mustard therapy in the treatment of lymphomas and leukemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

The nitrogen mustards; clinical use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Treatment of malignant disease with nitrogen mustard

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Recent advances in the management of lymphomas and leukemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Treatment of the inoperable pulmonary cancer, primary and metastatic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Nitrogen-mustard therapy for Hodgkin's disease, lymphosarcoma, the leukemias, and other disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

The nitrogen mustards in the treatment of leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Oral treatment of polycythaemia vera with beta-naphthyl-di-2-chloroethylamine (R48).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Clinical and hematologic effects of triethylene melamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Clinical observations on the use of triethylenemelamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Further observations on the use of triethylene melamine in neoplastic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Triethylenemelamine in polycythemia vera; a therapeutic trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Clinical use of triethylene melamine; report of seventy-five cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Treatment of polycythemia vera with triethylene melamine; summary of thirty cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Triethylene melamine in the treatment of lymphomas and other neoplastic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Triethylene melamine in bronchogenic carcinoma with vena caval obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Triethylene melamine in the treatment of neoplastic disease; a compound with nitrogen-mustardlike activity suitable for oral and intravenous use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Triethylene melamine in the treatment of lymphomas and leukemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Triethylene melamine therapy in Hodgkin's and other malignant diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Clinical studies on triethylenephosphoramide and diethylenephosphoramide, compounds with nitrogen-mustard-like activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Treatment of leukemia with triethylene thiophosphoramide (thio-TEPA); preliminary results in experimental and clinical leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Triethylenethiophosphoramide in the treatment of chronic leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Chemotherapy of Solid Tumors with Triethylene Thiophosphoramide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Clinical studies of triethylenethiophosphoramide in the treatment of inoperable cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

The effect of 1,4-dimethanesulfonyloxybutane (GT-41 or myleran) upon leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

Myleran in chronic myeloid leukaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2934569-2

10.1016/S0025-7125(16)34569-2

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:13308491%20AND%20SRC:MED&resulttype=core&format=json

8 November 2019

1 reference